BioStock: Saniona selects clinical candidate for major depressive disorder

After encouraging results showing rapid reversal of stress-induced depression, Saniona selects SAN2465 as a clinical candidate for major depressive disorder. The announcement comes less than a week after Saniona chose SAN2355 as the first clinical candidate from its Kv7 epilepsy program. BioStock reached out to Saniona’s CEO Thomas Feldthus for a comment.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2024/01/saniona-selects-clinical-candidate-for-major-depressive-disorder/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/